Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natarajan Ravendhran

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b StudyRohit Loomba, Arun J Sanyal, Atsushi Nakajima, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Hepatology (Baltimore, Md.)|November 9, 2015
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 dataJulius M Wilder, Lennox J Jeffers, Natarajan Ravendhran, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b StudyRohit Loomba, Arun J Sanyal, Atsushi Nakajima, et al.
Annals of Hepatology|October 15, 2016
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infectionMaribel Rodriguez-Torres, Eric Lawitz, Bienvenido Yangco, et al.
The Lancet. Gastroenterology & Hepatology|June 4, 2018
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1Marc Bourlière, Stuart C Gordon, Eugene R Schiff, et al.
Lancet (London, England)|August 10, 2010
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialPaul Y Kwo, Eric J Lawitz, Jonathan McCone, et al.
Hepatology (Baltimore, Md.)|April 14, 2011
Racial differences in hepatitis C treatment eligibilityMichael T Melia, Andrew J Muir, Jonathan McCone, et al.
Antiviral Therapy|February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trialRobert A Ogert, John A Howe, John M Vierling, et al.
Hepatology (Baltimore, Md.)|January 24, 2015
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III studyDavid R Nelson, James N Cooper, Jacob P Lalezari, et al.
JHEP Reports : Innovation in Hepatology|March 21, 2024
Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responsesMan-Fung Yuen, Scott Fung, Xiaoli Ma, et al.
The New England Journal of Medicine|June 1, 2017
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV InfectionMarc Bourlière, Stuart C Gordon, Steven L Flamm, et al.
Pageof 3